Perspective Therapeutics (CATX) Accounts Payables (2011 - 2026)

Perspective Therapeutics has disclosed Accounts Payables across 16 years of filings, most recently posting $26.5 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $26.5 million, up 203.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.5 million (up 203.24% YoY), and the FY2025 annual result was $20.5 million, up 98.31% from the prior year.
• Accounts Payables came in at $26.5 million for Q1 2026 at Perspective Therapeutics, up from $20.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $26.5 million in Q1 2026 to a low of $150000.0 in Q2 2022.
• The 5-year median for Accounts Payables is $6.1 million (2024), against an average of $7.9 million.
• Across the five-year window, Accounts Payables slumped 73.83% in 2022 and soared 6913.83% in 2024, its largest moves.
• Perspective Therapeutics' Accounts Payables stood at $233000.0 in 2022, then jumped by 2865.24% to $6.9 million in 2023, then soared by 49.7% to $10.3 million in 2024, then surged by 98.31% to $20.5 million in 2025, then rose by 29.13% to $26.5 million in 2026.
• The last three Accounts Payables figures came in at $26.5 million (Q1 2026), $20.5 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.